AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02110433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordiva System (R)
Description: Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
Study NCT02110433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordiva System (R)
Description: Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
Study NCT00653575 — intervention group
Intervention type: BEHAVIORAL
Intervention: Traumagenic Dynamics model
Description: The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
Study NCT01841294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Description: Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
Study NCT01841294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
Study NCT04037007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy - High experienced.
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
Study NCT04037007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy - Low experienced.
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
Study NCT04037007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (guidewire) cannulation- High experienced
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
Study NCT03123458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: clonal fetal MSCs
Study NCT03870867 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04023643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation Weaning
Description: Use of different weaning strategies
Study NCT04023643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation Weaning
Description: Use of different weaning strategies
Study NCT01303757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counselling
Study NCT01303757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Study NCT01199679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosectomy
Description: Endoscopic mucosal resection in the upper GI tract.
Study NCT01199679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation
Description: Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
Study NCT01284621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BI 10773
Description: medium dose, oral administration
Study NCT01284621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Medium dose oral administration on day 2-5
Study NCT01284621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: medium dose oral administration
Study NCT01284621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Low dose oral administration on day 1
Study NCT04838548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study NCT02110433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BNP heartcheck
Description: Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
Study NCT04557878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Dextrose Solution
Description: Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
Study NCT04557878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Phase Concentrated Growth Factor (LPCGFs)
Description: Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
Study NCT00687323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT03329573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets A
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
Study NCT03332238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stomal Vascular Fraction Material
Description: Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
Study NCT03332238 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's solution
Description: Ringer's solution
Study NCT01067287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
Study NCT01067287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cell Fusion Vaccine
Description: One week following each infusion of CT-011
Study NCT04037007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (guidewire) cannulation - Low experienced
Description: We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
Study NCT04246125 — intervention group
Intervention type: PROCEDURE
Intervention: Interventional radiology : skin dose measurements
Description: Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program.
Study NCT02051738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fasted state (Treatment A)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
Study NCT02051738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fed state (Treatment B)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
Study NCT04176406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used
Study NCT04653389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
Study NCT04176406 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study NCT05214703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold therapy application
Description: cold therapy
Study NCT02316665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: continuous positive airway pressure treatment during three months with adherence recording
Study NCT04653389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first TACE and Sintilimab Injection will be initiated simultaneously.
Study NCT04653389 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
Study NCT02215616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
Study NCT02215616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
Study NCT02215616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
Study NCT00519610 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Patients' charts will be reviewed for relevant medical information.
Study NCT05920200 — intervention group
Intervention type: PROCEDURE
Intervention: open non-mesh hernia repair
Description: A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
Study NCT02316665 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure
Description: Sham-continuous positive airway pressure during three months with adherence recording
Study NCT04278950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
Study NCT04278950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo will be 2.5mL of saline with brown food coloring.
Study NCT05920200 — intervention group
Intervention type: PROCEDURE
Intervention: open mesh hernia repair
Description: A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures.
Study NCT04365777 — intervention group
Intervention type: OTHER
Intervention: OAA/S=5
Description: Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
Study NCT04365777 — intervention group
Intervention type: OTHER
Intervention: OAA/S=3
Description: Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
Study NCT04365777 — intervention group
Intervention type: OTHER
Intervention: OAA/S=1
Description: Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
Study NCT04245956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire
Description: The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
Study NCT00599378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intentions-based telephone counseling
Description: Implementation Intentions-based telephone counseling
Study NCT01749917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Exercise program An brief exercise session including proprioceptive and dexterity activities
Study NCT00426868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct injection of ADRCs into the Left Ventricle
Description: Dose escalation
Study NCT01749917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Active upper limb range of movement exercises for 15 minutes.
Study NCT00968799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraoperative intraperitoneal chemotherapy
Description: Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
Study NCT00968799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Surgical removal of tumor nodules~including resection of organs infested with tumor
Study NCT00968799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is applied as chemotherapy during surgery
Study NCT00426868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Direct injection of placebo into the Left Ventricle
Study NCT01413243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: Trichuris suis ova 2500 eggs every 2 weeks
Study NCT01126411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immunoadsorption / immunglobulin substitution
Description: Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
Study NCT01413243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichuris suis ova
Description: Trichuris suis ova 2500 eggs every 2 weeks
Study NCT05002985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study NCT00460655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: botulinum toxin type A
Study NCT00460655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03544905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33 for tablet
Description: 1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
Study NCT04265248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
Study NCT04265248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The subjects will perform evidence-based exercises for the neck.
Study NCT05920200 — intervention group
Intervention type: PROCEDURE
Intervention: MIS hernia repair
Description: A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation .
Study NCT03329573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets B
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
Study NCT02914470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbplatin, cyclophophamide, atezolizumab
Study NCT01311479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulation Therapy
Description: Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
Study NCT03589872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fine motor dexterity test, nine hole peg test
Description: The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
Study NCT02318745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Informed Family Treatment for Adolescents
Description: Family Therapy, Psycho-educational Modules, Individual therapy sessions
Study NCT02318745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Treatment
Description: Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
Study NCT03926260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Description: blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
Study NCT01574937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 28 day cycle
Study NCT01574937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 28 day cycle
Study NCT04834050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris isometric home-based exercise
Description: All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
Study NCT03514238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Aerobic Exercise (HIIT)
Description: Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
Study NCT01380678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional injection of bevacizumab
Description: single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
Study NCT01380678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical antihistamine and vasoconstrictor
Description: combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
Study NCT03514238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Aerobic Exercise (MOD)
Description: 35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
Study NCT03514238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Sitting Condition (C)
Description: Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).